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Abstract
Background: In lung cancer, a patient’s survival is poor with a wide variation in survival within the stage of disease. The aim
of this study was to investigate the familial concordance in lung cancer survival by means of analyses of pairs with different
degrees of familial relationships.
Methods: Our population-based Swedish family database included three million families and over 58 100 lung cancer
patients. We modelled the proband (parent, sibling, spouse) survival utilizing a multivariate proportional hazard (Cox) model
adjusting for possible confounders of survival. Subsequently, the survival in proband’s relative (child, sibling, spouse) was
analysed with a Cox model.
Findings: By use of Cox modelling with 5 years follow-up, we noted a decreased hazard ratio for death in children with
good parental survival (Hazard Ratio [HR]=0.71, 95% CI=0.51 to 0.99), compared to those with poor parental survival. Also
for siblings, a very strong protective effect was seen (HR=0.14, 95% CI=0.030 to 0.65). Finally, in spouses no correlation in
survival was found.
Interpretation: Our findings suggest that genetic factors are important in lung cancer survival. In a clinical setting,
information on prognosis in a relative may be vital in foreseeing the survival in an individual newly diagnosed with lung
cancer. Future molecular studies enhancing the understanding of the underlying mechanisms and pathways are needed.
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Introduction
Lung cancer remains the leading cause of death in the Western
world and in spite of adequate surgery, adjuvant chemotherapy
and radiotherapy, outcome remains poor with 5-year overall
survival rates of less than 20% [1–3]. Important factors influencing
lung cancer survival will include metastatic potential of the
tumour, response to treatment, behavioural and sociodemographic
characteristics [1].
The genetic background of a patient with lung cancer might be
essential for the ability of the tumour to metastasis, since generally
the mechanism by which cells try to colonise at distant sites is
surprisingly inefficient [4–7]. Recently, several molecular studies
have found genetic factors associated with lung cancer survival [8–
12], and previously published data from our group on familial
survival concordance in parents and children with lung cancer
does not distinguish but implies the importance of both genetic
and environmental factors [13]. Smoking is truly the main
environmental risk factor for lung cancer, nonetheless the overall
effect of smoking on lung cancer survival has been seen to at most,
in certain histologies and in women, increase the risk of dying with
around 30% [14–16].
As a first nation-wide Swedish population-based epidemiolog-
ical study, we analysed the familial correlation in lung cancer
survival. Our aim was to disentangle the importance of genetic
and environmental factors in lung cancer survival by analysing
family pairs with different degree of relationship.
Methods
Swedish population-based family data
Linkage of different records of personal information is possible
in Sweden as each resident has a unique national registration
number. Our study is based on a record linkage between several
population-based registers; the Multi-Generation Register, the
Swedish Cancer Register, the Cause of Death Register, and the
Migration Register. Finally, additional linkages were made to the
Censuses of 1960, 1970, 1980 and 1990 that holds information on
individual socioeconomic status.
The Multi-Generation Register includes individuals born in
Sweden from January 1932 through December 2001 with their
biological parents. The proportion of false paternity is not known
in the study cohort, but has been estimated to account for less than
5% in other European countries with similar registers [17,18].
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5588Incident cancers in Sweden since 1958 have been reported to
the Swedish Cancer Register using a four digit diagnostic code
according to the 7
th revision of the International Classification of
Diseases (ICD-7), together with information on histopathological
type. In the 1970s, the completeness of cancer registration (with
cytological or histological verification) was assessed to be around
95% and has been regarded to be close to 100% since the 1990s
[19]. In our study, lung cancer was defined as cancers coded as
ICD-7 162 and tumour histology was categorised into five groups;
adenocarcinoma (histopathological type 096), squamous cell
carcinoma (histopathological type 146), small cell carcinoma
(histopathological type 186), large cell carcinoma (histopatholog-
ical type 196) and other histology. Deaths caused by lung cancer
(underlying cause of death) were collected from the Cause of
Death Register, which has a reported accuracy of 96% from 1961
onwards [20–22]. Information on cause of death was ascertained
from death certificates filled in by treating physicians.
In the Multi-Generation Register each child exists only once
while parents are present as many times as they have children. An
individual can be in the database both as offspring and parent and
parents are those that admit to parenthood at birth, thus not only
married individuals. Our database comprised over 11 million
individuals organized into around three million families, including
more than 58 100 lung cancer patients.
Because treatment and thus survival may differ geographically
in Sweden, area of diagnosis was obtained from the Cancer
Register and categorized into 6 health care regions as defined by
the health care structure of Sweden. Socioeconomic status was
given in the Censuses and was categorized into following groups;
blue collar workers, white collar workers, self employed, farmers
and others.
Statistical analysis
From our database we selected all pairs of parent-child, siblings
and spouses concordantly diagnosed with a first primary invasive
lung cancer. The outcome of interest was cause-specific lung
cancer death within 5-years because it is a clinically relevant
measure. The person-time at risk started at the date of lung cancer
diagnosis and continued until emigration, end of follow-up
(December 31, 2001), or death, whichever came first. In our
register-based study we have complete follow-up. Out of 439
parent-child pairs, 63 sibling pairs, and 525 spouse pairs, 60
parents and 60 children, six younger siblings and nine older
siblings and 90 husbands and 62 wives were censored, respectively.
The rest of the individuals were either followed until end of follow-
up or died due to lung cancer.
We limited our follow-up back to 1961 since the Cause of Death
Registry has a high reported accuracy of 96% from 1961 onwards.
We restricted our offspring analysis to 1991 and onwards, because
complete data for parents of children who died from 1991 are
available in the Multi-Generation Register, whereas before this
date the data are incomplete. Accordingly, both children and
siblings in our analyses were diagnosed between January 1991 and
December 2001, while for parents and spouses the follow-up was
unrestricted (January 1961 to December 2001). We selected
husbands as proband for consistency with sibling analyses (oldest
sibling was defined as proband) since generally husbands are older
than their wives.
The survival in the proband (parent, sibling, spouse) was
modelled employing a multivariate proportional hazards (Cox)
model adjusting for the calendar year of diagnosis and age at
diagnosis. The residuals from this model were used to describe
proband survival compared with the cumulative baseline hazard,
adjusting for calendar year of diagnosis and age at diagnosis,
resulting in residual values below, above, and around zero. We,
subsequently, categorized proband survival by defining groups
according to quartiles of survival, with the better than expected
survival group as the best quartile of survival, the expected survival
group as the middle two quartiles of survival, and the worse than
expected survival group as the worst quartile of survival. For
simplicity, we refer to these categories as good, expected and poor.
Depending on the modelled survival in proband the survival in
proband’s relative (child, sibling, spouse) was analysed with a
multivariate proportional hazard model adjusting for possible
confounders on survival such as calendar year of diagnosis, age at
diagnosis, socioeconomic factors, county of diagnosis, tumour
histology and gender.
The proportional hazard assumption for the main exposure
variable was assessed using Schoenfeld’s test statistics [23]; no
significant deviation was noted for the family pairs studied. A level
of 5% statistical significance was used. All data preparation and
analysis was done using the SAS Statistical package, version 9.1,
whereas Stata was used to test the proportional hazards
assumption.
Results
The number of parent-child, sibling and spouse pairs diagnosed
with lung cancer and number of lung cancer-specific deaths are
presented in Table 1. Descriptive factors such as period and age at
diagnosis, tumour histology, socioeconomic status and gender
distributions in relative pairs with lung cancer are presented in
Table 2.
The hazard ratio in the proband’s relative (child, sibling, spouse)
depending on proband survival, was estimated by use of a
multivariate (Cox) model, see Table 3. In the parent-child analyses
(adjusting for calendar year of diagnosis, age at diagnosis,
socioeconomic factors, county of diagnosis, tumour histology and
gender) children with good parental survival had a decreased
hazard ratio for death of 0.71 (95% CI=0.51 to 0.99), compared
to children with poor parental survival. Also, in siblings, with good
proband survival, the hazard ratio for death was significant at 0.14
(95% CI=0.030 to 0.65). Finally, in spouses, no significant effect
on spouse survival was seen. Choosing the proband spouse to be
husband or wife had no impact on the results (results not shown).
Adjusting the proband multivariate proportional hazards (Cox)
model for all covariates such as calendar year of diagnosis, age at
diagnosis, socioeconomic factors, county of diagnosis, tumour
Table 1. Characteristics of parent-child, sibling and spouse
pairs with primary lung cancer diagnosed in Sweden.
Pairs of relatives
Pairs with
lung cancer
Concordant
alive
Concordant
dead
All lung cancer
Parent
a-Child
b 439 32 256
Sibling-Sibling
b 63 13 30
Spouse-Spouse
a 525 39 301
Non-small cell lung cancer
Parent
a-Child
b 358 28 205
Sibling-Sibling
b 49 12 18
Spouse-Spouse
a 414 30 244
aParents (Spouses) diagnosed between January 1961 and December 2001.
bChildren (siblings) diagnosed between January 1991 and December 2001.
doi:10.1371/journal.pone.0005588.t001
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somewhat wider confidence intervals. Children, siblings and
spouses with good proband survival had a decreased hazard ratio
for death of 0.743 (95% CI=0.532 to 1.039), 0.183 (95%
CI=0.045 to 0.736) and 0.87 (95% CI=0.651 to 1.150),
respectively.
We performed additional sub-analyses only including non-small
cell lung cancer. In the non-small cell lung cancer analyses
children, siblings and spouses with good proband survival had a
decreased hazard ratio for death of 0.69 (95% CI=0.48 to 0.99),
0.13 (95% CI=0.019 to 0.94) and 0.78 (95% CI=0.56 to 1.07)
respectively, compared to children, siblings and spouses with poor
proband survival. In none of these analyses a significant trend for
the categories good, median and poor survival was achieved. We
had no power to separately analyse small cell lung cancer.
Discussion
In this Swedish population-based study, we show that lung
cancer survival in an individual is dependent on the lung cancer
survival in his/her parent or sibling. However, no survival
correlation was seen in spouses. Our large population-based study
has several strengths, including an almost complete ascertainment
of cancers along with a complete follow-up of lung cancer patients.
Our estimates were robust showing only small differences when
contrasting the fully adjusted model, which included calendar year
of diagnosis, age at diagnosis, socioeconomic factors, county of
diagnosis, tumour histology and gender, with the unadjusted
model (only adjusted for calendar year of diagnosis and age at
diagnosis). Since Swedish national registries are highly complete
and accurate [19–22] and Swedish lung cancer survival increase
has been modest [24], we believe that our retrospective cohort
study of cancer prognosis will be almost as accurate as had we
performed the same study in a prospective setting.
A limitation of our study was the absence of information on
stage of disease as well as treatment because such information is
not included in the Swedish Cancer Register and therefore not in
our database. However, since the routinely used prognosticators
for lung cancer poorly describe lung cancer outcome compared to
many other malignancies this may not have effected the results or
their interpretation. In addition, we argue that adjusting for such
covariates in the analysis is inappropriate. If familial clustering of
prognosis reflects a genuine biologic phenomenon, it should be
mirrored in established prognostic factors and adjusting for them
Table 2. Period, age, histology, socioeconomic status and gender distributions in relative pairs with lung cancer.
Relative pairs
Parent - Child Sibling - Sibling Spouse – Spouse
Parent Child Older sibling Younger sibling Husband Wife
Period
1961–1969 59 (13%) 45 (9%) 31 (6%)
1970–1979 117 (27%) 103 (20%) 65 (12%)
1980–1989 155 (35%) 157 (30%) 175 (33%)
1991–2001 108 (25%) 439 (100%) 63 (100%) 63 (100%) 220 (42%) 254 (48%)
Age
,50 7 (2%) 94 (21%) 12 (19%) 21 (33%) 23 (4%) 34 (6%)
50–59 58 (13%) 235 (54%) 29 (46%) 31 (49%) 103 (20%) 106 (20%)
60–69 148 (34%) 110 (25%) 22 (35%) 11 (17%) 193 (37%) 191 (36%)
70+ 226 (51%) 206 (39%) 194 (37%)
Mean age 76 60 61 58 73 72
Tumour histology
Adenocarcinoma 76 (17%) 167 (38%) 29 (46%) 22 (35%) 88 (17%) 133 (25%)
Squamous cell carcinoma 155 (35%) 75 (17%) 13 (21%) 11 (17%) 195 (37%) 123 (23%)
Small cell carcinoma 24 (6%) 61 (14%) 9 (14%) 9 (14%) 45 (9%) 75 (14%)
Large cell carcinoma 143 (33%) 106 (24%) 9 (14%) 16 (25%) 149 (28%) 141 (27%)
Other 41 (9%) 30 (7%) 3 (5%) 5 (8%) 48 (9%) 53 (10%)
Socioeconomic status (SES)
Blue collar workers 242 (55%) 183 (42%) 28 (44%) 35 (56%) 284 (54%) 253 (48%)
White collar workers 95 (22%) 172 (39%) 24 (38%) 17 (27%) 137 (26%) 180 (34%)
Self employed 37 (8%) 25 (6%) 2 (3%) 3 (5%) 55 (10%) 44 (8%)
Farmers 24 (5%) 1 (0%) 0 (0%) 1 (2%) 11 (2%) 12 (2%)
Others 41 (9%) 58 (13%) 9 (14%) 7 (11%) 38 (7%) 36 (7%)
Gender
Female 112 (26%) 219 (50%) 38 (60%) 37 (59%) 525 (100%)
Male 327 (74%) 220 (50%) 25 (40%) 26 (41%) 525 (100%)
doi:10.1371/journal.pone.0005588.t002
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information may have allowed a deeper understanding of the
biologic mechanisms by which prognostic outcome is determined
by cancer survival among probands.
Another potential limitation in the present study is the absence
of information about smoking. However, we argue that our
inability to adjust for smoking habits will have only minor effects
on our results for several reasons. Firstly, the impact of smoking on
lung cancer survival seems to be dependent on a number of factors
such as sex, histological type and years since smoking cessation
[14–16,25] and the overall effect of smoking on lung cancer
survival has been seen to at most, in certain histologies and in
women, increase the risk with around 30% of dying [14–16].
Secondly, even if smoking is a truly established risk factor for lung
cancer initiation, with strongly elevated disease risk observed
among smokers, familial cases of lung cancer can not be attributed
to shared smoking habits [26]. Finally, previous reports do not
support higher correlation of smoking habits between siblings or
parent-offspring’s as compared to spouses [27–32].
Genetic variation has been associated with lung cancer survival.
Recently, fifteen SNPs in the DNA repair pathway were associated
with a significantly greater overall survival [33], and five gene
signatures closely associated with relapse-free and overall survival
among lung cancer patients were unravelled [34]. Also, the EGFR
gene polymorphic simple sequence repeat (SSR) length [11], the
Y/X polymorphism of the innate-immunity gene MBL2 with
haplotypes [10], and glutathione-related genes have been
associated with improved lung cancer survival [35].
The genetic background of an individual may influence the
metastatic ability of a tumour. Moreover, allelic variants might
modify the likelihood of tumour metastasis occurring through vital
secondary events, such as deletions, amplifications, and epigenetic
modulations in the metastatic cascade. Genetic variations may also
affect the immune response, because small variations in the ability
of an individual to mount an effective cytolytic defence, together
with the tumour cell’s ability to downregulate specific antigens,
might be important in the metastatic cascade [36]. In addition, it is
not unreasonable to hypothesize that response to therapy may be
partly inherited. Interestingly, in a recent study, non-small-cell
lung cancer (NSCLC) patients homologous for the ERCC1 118
(excision repair cross-complementing 1) exhibited a significantly
better survival [37].
In conclusion, analyses of pairs with different familial relation-
ships enable the distinction of genetic and environmental factors.
Our findings suggest that genetic factors are important in lung
cancer survival. Consequently, molecular understanding of the
underlying mechanisms and pathways would help to better foresee
the individual lung cancer prognosis.
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